Ann: Appendix 4D and Half Year Accounts, page-24

Ha (bows) when you put it so politely how can I not acquiesce to your request. I agree that with the recent transaction it is now a past issue (which incidentally is why I believe the company agreed to it, just to say “look let’s just move on”).

There are plenty of things that I can think of that Kza would have that nox would find useful in taking the drug forward, such as results from a myriad of preclinical testing and clinical trial data performed by novogen through the years.